UK: Patents granted to Doudna-Charpentier

The United Kingdom’s Intellectual Property Office awarded two patents to the Doudna-Charpentier team, with the first UK patent covering the single-guide RNA format of the CRISPR-Cas9 system and its use in any environment (including plant, animal and human cells). This patent also includes claims covering the use of CRISPR-Cas9 in producing medicines for treating disease. A second UK patent focuses on modified Cas9 that incorporates additional DNA-modulating functions such as the regulation of gene expression.



Sign up to receive updates from the CRISPR Collective

Related News

U.S. patent office issued third CRISPR patent to CVC; indicates it will issue a fourth
“Europe: Legal issues lead to invalidation of second Broad patent; significant reduction in scope of third Broad patent”
U.S. patent office indicates it will issue third CRISPR patent to UC
Read moreArrow-down